share_log

Truist Securities Upgrades Corcept Therapeutics to Buy, Raises Price Target to $38

Benzinga ·  Nov 6, 2023 08:07

Truist Securities analyst Joon Lee upgrades Corcept Therapeutics (NASDAQ:CORT) from Hold to Buy and raises the price target from $29 to $38.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment